Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luana Fianchi

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Blood Cancer Journal|July 19, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian studyLivio Pagano, Marianna Criscuolo, Alessandro Broccoli, et al.
Cancers|July 14, 2023
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM ExperienceLuana Fianchi, Fabio Guolo, Francesco Marchesi, et al.
American Journal of Hematology|July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systemsRena Buckstein, Enrico Balleari, Richard Wells, et al.
American Journal of Hematology|April 16, 2026
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International ExperienceBruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, et al.
Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Journal of Fungi (Basel, Switzerland)|December 30, 2020
Polymorphisms within the <i>TNFSF4</i> and <i>MAPKAPK2</i> Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics ConsortiumJose Manuel Sánchez-Maldonado, Ana Moñiz-Díez, Rob Ter Horst, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Blood Cancer Journal|July 19, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian studyLivio Pagano, Marianna Criscuolo, Alessandro Broccoli, et al.
Cancers|July 14, 2023
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM ExperienceLuana Fianchi, Fabio Guolo, Francesco Marchesi, et al.
American Journal of Hematology|July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systemsRena Buckstein, Enrico Balleari, Richard Wells, et al.
American Journal of Hematology|April 16, 2026
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International ExperienceBruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, et al.
Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Journal of Fungi (Basel, Switzerland)|December 30, 2020
Polymorphisms within the <i>TNFSF4</i> and <i>MAPKAPK2</i> Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics ConsortiumJose Manuel Sánchez-Maldonado, Ana Moñiz-Díez, Rob Ter Horst, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Pageof 10